H558R 多态性与氟卡尼治疗房颤疗效及毒性的关联队列研究
该队列研究纳入 2017–2021 年某区域医疗区 104 例房颤且服用氟卡尼的患者,比较 H558R-/- 与 H558R+/- 患者 6 个月房颤复发或毒性复合终点。H558R 在房颤队列中的患病率显著高于一般人群,H558R+/- 与较低的 6 个月及长期复发或毒性风险相关。
要点
- 房颤患者中 H558R 多态性患病率显著高于一般人群。
- H558R+/- 患者 6 个月房颤复发或毒性风险显著低于 H558R-/-。
- 长期随访中 H558R+/- 仍显示较低复发或毒性风险。
核心结论
- H558R 多态性在房颤患者中较一般人群更常见,且其存在与氟卡尼治疗更有利的反应相关。
研究设计与样本
- 队列研究纳入 2017–2021 年某区域医疗区诊断为房颤并处方氟卡尼的患者 104 例。
- 比较 H558R-/- 与 H558R+/- 患者,主要终点为 6 个月房颤复发或毒性复合终点。
- 将房颤队列 H558R 患病率与一般人群样本(n=3401)比较。
主要发现
- 104 例中 H558R-/- 占 57%,H558R+/- 占 37%,H558R+/+ 占 6%。
- 房颤队列 H558R 患病率 43.27%,一般人群 24.37%,患病率比 1.78(95%CI 1.41–2.23,p<0.01)。
- H558R+/- 患者 6 个月房颤复发或毒性风险显著降低(p=0.023,风险比 0.423,95%CI 0.189–0.947),绝对风险差 21.5%。
- 多变量分析结果相似;长期随访 H558R+/- 仍显示较低风险(p=0.039,HR 0.53,95%CI 0.276–0.999)。
临床怎么用
- 对房颤患者处方氟卡尼前可考虑 H558R 基因型信息以评估复发或毒性风险。
- H558R+/- 患者可能从氟卡尼治疗中获得更有利的疗效与安全性平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The SCN5A gene polymorphism histidine-558-to-arginine (H558R) has been associated with atrial fibrillation (AF) and may affect the therapeutic effects of flecainide. This study aimed to assess the prevalence of the H558R polymorphism in a European cohort of patients with AF and examine its association with flecainide's effects on AF recurrence and toxicity. METHODS: This cohort study included patients diagnosed with AF and prescribed flecainide between 2017 and 2021 in a regional health area. Patients without the polymorphism (H558R-/-) were compared with heterozygous patients (H558R+/-) for a primary outcome of combined 6-month AF recurrence or toxicity. Secondary analyses evaluated the long-term outcomes and compared the prevalence of H558R in the AF cohort to a general population sample (n=3401). RESULTS: A total of 104 patients were enrolled, with 57% H558R-/-, 37% H558R+/- and 6% H558R+/+. The prevalence of the H558R polymorphism was significantly higher in the AF cohort than in the general population (43.27% vs 24.37%, prevalence ratio 1.78, 95% CI 1.41 to 2.23, p<0.01). H558R+/- patients had a significantly lower risk of 6-month AF recurrence or toxicity (p=0.023, risk ratio 0.423, 95% CI 0.189 to 0.947), corresponding to an absolute risk difference of 21.5%. These findings were similar in the multivariable analysis. In long-term follow-up, H558R+/- patients continued to demonstrate a lower risk of AF recurrence or toxicity (p=0.039, HR 0.53, 95% CI 0.276 to 0.999). CONCLUSIONS: The H558R polymorphism is more prevalent in patients with AF compared with the general population and its presence is associated with a more favourable response to flecainide treatment.
引用
- Trincado Ave M, Brion M, Blanco-Verea A, et al. Prevalence and relevance of H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study. Heart. 2025. PMID: 39486891. doi:10.1136/heartjnl-2024-324506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。